Imatinib Mesylate for the Treatment of Steroid-Refractory Sclerotic-Type Cutaneous Chronic Graft-versus-Host Disease Kristin Baird, Leora E. Comis, Galen.

Slides:

Advertisements

Similar presentations

National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis.

Advertisements

Stephanie J. Lee, Loretta A. Williams

A Multicenter Pilot Evaluation of the National Institutes of Health Chronic Graft-versus- Host Disease (cGVHD) Therapeutic Response Measures: Feasibility,

In Stem Cell Transplantation by Limiting the Morbidity of Graft-versus-Host Disease Tolerance to Myeloablative Conditioning is Improved Nicolas Novitzky,

A Prospective Study of Iron Overload Management in Allogeneic Hematopoietic Cell Transplantation Survivors Navneet S. Majhail, Hillard M. Lazarus, Linda.

Pharmacokinetics of Ganciclovir after Oral Valganciclovir versus Intravenous Ganciclovir in Allogeneic Stem Cell Transplant Patients with Graft-versus-Host.

A Multicenter Pilot Evaluation of the National Institutes of Health Chronic Graft-versus- Host Disease (cGVHD) Therapeutic Response Measures: Feasibility,

Efficacy of Rituximab in the Setting of Steroid-Refractory Chronic Graft-versus-Host Disease: A Systematic Review and Meta-Analysis Mohamed A. Kharfan-Dabaja,

Single and Multiple Dose MultiStem (Multipotent Adult Progenitor Cell) Therapy Prophylaxis of Acute Graft-versus-Host Disease in Myeloablative Allogeneic.

David Myerson, Gideon Steinbach, Ted A. Gooley, Howard M. Shulman

Voriconazole-Induced Phototoxicity Masquerading as Chronic Graft-versus-Host Disease of the Skin in Allogeneic Hematopoietic Cell Transplant Recipients

Unique Abnormalities of CD4+ and CD8+ Central Memory Cells Associated with Chronic Graft-versus-Host Disease Improve after Extracorporeal Photopheresis

Sympathectomy Protects Denervated Skin from Graft-Versus-Host Disease

Safety and Efficacy of Infliximab Therapy in the Setting of Steroid-Refractory Acute Graft-versus-Host Disease Fevzi F. Yalniz, Mehrdad Hefazi, Kristen.

Successful Treatment of Severe Acute Intestinal Graft-versus-Host Resistant to Systemic and Topical Steroids with Alemtuzumab Marc Schnitzler, Jens Hasskarl,

National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis.

Dasatinib as Salvage Therapy for Steroid Refractory and Imatinib Resistant or Intolerant Sclerotic Chronic Graft-versus-Host Disease Isabel Sánchez-Ortega,

Salivary Gland Involvement in Chronic Graft-Versus-Host Disease: Prevalence, Clinical Significance, and Recommendations for Evaluation Matin M. Imanguli,

B Cells in Chronic Graft-versus-Host Disease

Oral Manifestations Compatible with Chronic Graft-versus-Host Disease in Patients with Fanconi Anemia Laura Grein Cavalcanti, Renata L. Fuentes Araújo,

Sabina Kersting, Leo F. Verdonck

Mark Pines, David Snyder, Shai Yarkoni, Arnon Nagler

Characterization and Risk Factor Analysis of Osteoporosis in a Large Cohort of Patients with Chronic Graft-versus-Host Disease Filip Pirsl, Lauren M.

Bisphosphonate Therapy for Reduced Bone Mineral Density in Children with Chronic Graft-versus-Host Disease Paul A. Carpenter, Paul Hoffmeister, Charles.

Musculoskeletal, Neurologic, and Cardiopulmonary Aspects of Physical Rehabilitation in Patients with Chronic Graft-versus-Host Disease Sean Robinson.

National Institutes of Health Chronic Graft-versus-Host Disease Staging in Severely Affected Patients: Organ and Global Scoring Correlate with Established.

Extracorporeal Photopheresis in Steroid-Refractory Acute or Chronic Graft-versus-Host Disease: Results of a Systematic Review of Prospective Studies

Stephanie J. Lee, Loretta A. Williams

Impact of Age on Quality of Life, Functional Status, and Survival in Patients with Chronic Graft-versus-Host Disease Areej El-Jawahri, Joseph Pidala,

Reduced-Intensity Allogeneic Stem Cell Transplantation in Children and Young Adults with Ultrahigh-Risk Pediatric Sarcomas Kristin Baird, Terry J. Fry,

Pulse Cyclophosphamide for Steroid-Refractory Chronic Graft-Versus-Host Disease Nelson J. Chao, MD, MBA, Yevgeniya Gora Foster, MD, Krista Rowe, RN, MSN,

Role of the Mycobiome in Human Acute Graft-versus-Host Disease

Safety and Effectiveness of Vedolizumab in Patients with Steroid-Refractory Gastrointestinal Acute Graft-versus-Host Disease: A Retrospective Record Review

David Gómez-Almaguer, Guillermo J

Dysglycemia Following Glucocorticoid Therapy for Acute Graft-versus-Host Disease Adversely Affects Transplantation Outcomes Joseph Pidala, Jongphil Kim,

Measuring Therapeutic Response in Chronic Graft-versus-Host Disease

A Novel Strategy in Managing Post-Liver Transplant Acute Graft-Versus-Host-Disease: The New Era (T)Rojan Horse Zeyad Kanaan, MD, William Tse, MD, FACP

Reprint of: B Cells in Chronic Graft-versus-Host Disease

Paul J. Martin, Terry Furlong, Scott D. Rowley, Steven A

Etanercept plus Topical Corticosteroids as Initial Therapy for Grade One Acute Graft- Versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation

Graft-versus-Host Disease Induced Graft-versus-Leukemia Effect: Greater Impact on Relapse and Disease-Free Survival after Reduced Intensity Conditioning

Iron Overload Manifesting as Apparent Exacerbation of Hepatic Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation Rammurti.

Outcomes of Maintenance Therapy with Bortezomib after Autologous Stem Cell Transplantation for Patients with Multiple Myeloma Dharshan Sivaraj, Michael.

Myeloablative Transplantation using either Cord Blood or Bone Marrow leads to Immune Recovery, High Long-Term Donor Chimerism and Excellent Survival in.

Mohammad Alhyari, M. D. , Aymen Bukannan, M. D. , Kimberly Brown, M. D

Low-Dose IL-2 Therapy Preferentially Improves Diversity of the Regulatory T Cell Repertoire in Patients with Refractory Chronic Graft-Versus-Host Disease

What is quality in a transplant program?

Issues of Aging and Geriatric Medicine: Relevance to Cancer Treatment and Hematopoietic Reconstitution William B. Ershler, Andrew S. Artz, Evan T. Keller

Content Validity of the Lee Chronic Graft-versus-Host Disease Symptom Scale as Assessed by Cognitive Interviews Emily C. Merkel, Sandra A. Mitchell,

Heterogeneity in Studies of Mesenchymal Stromal Cells to Treat or Prevent Graft- versus-Host Disease: A Scoping Review of the Evidence Mina Rizk, Madeline.

Unrelated Stem Cell Transplantation after a Reduced Intensity Conditioning Regimen Containing High-Dose Thymoglobulin Leads to Controllable Graft-versus-Host.

John E. Levine, Sophie Paczesny, Stefanie Sarantopoulos

Improved Outcome for Peripheral Blood Stem Cell Transplantation for Advanced Primary Myelodysplastic Syndrome Scott R. Solomon, Bipin N. Savani, Richard.

Manuel Jurado, Carlos Vallejo, José A

Blood and Marrow Transplant Handbook

Calcinuerin-Inhibitor (CI) Free Graft-Versus-Host Disease (GvHD) Prophylaxis: Its Effects on Magnesium, Renal Function, and the Cost of Care Marlee Muilenburg,

Young Female Donors Do Not Increase the Risk of Graft-versus-Host Disease or Impact Overall Outcomes in Pediatric HLA-Matched Sibling Hematopoietic Stem.

Preengraftment Syndrome after Unrelated Cord Blood Transplant Is a Strong Predictor of Acute and Chronic Graft-versus-Host Disease Haydar Frangoul, Li.

C-Reactive Protein Levels at Diagnosis of Acute Graft-versus-Host Disease Predict Steroid-Refractory Disease, Treatment-Related Mortality, and Overall.

Low Serum Levels of Total Rabbit-IgG Is Associated with Acute Graft-Versus-Host Disease after Unrelated Donor Hematopoietic Stem Cell Transplantation:

Combination Therapy for Graft-versus-Host Disease Prophylaxis with Etanercept and Extracorporeal Photopheresis: Results of a Phase II Clinical Trial

Mammen Chandy Biology of Blood and Marrow Transplantation

Yuri Fedoriw, T. Danielle Samulski, Allison M. Deal, Cherie H

Treatment versus Transplant for Challenging Hematologic Disorders

Prospective Monitoring of Tumor Necrosis Factor α and Interferon γ to Predict the Onset of Acute and Chronic Graft-versus-Host Disease after Allogeneic.

Oral Symptom Intensity, Health-Related Quality of Life, and Correlative Salivary Cytokines in Adult Survivors of Hematopoietic Stem Cell Transplantation.

Mary Eapen Biology of Blood and Marrow Transplantation

Endothelial Vulnerability and Endothelial Damage Are Associated with Risk of Graft- versus-Host Disease and Response to Steroid Treatment Sascha Dietrich,

Infliximab for Managing Steroid-Refractory Acute Graft-versus-Host Disease Joseph Pidala, Jongphil Kim, Teresa Field, Ali McBride, Mohamed Kharfan-Dabaja,

Biology of Blood and Marrow Transplantation

Presentation transcript:

Imatinib Mesylate for the Treatment of Steroid-Refractory Sclerotic-Type Cutaneous Chronic Graft-versus-Host Disease Kristin Baird, Leora E. Comis, Galen O. Joe, Seth M. Steinberg, Fran T. Hakim, Jeremy J. Rose, Sandra A. Mitchell, Steven Z. Pavletic, William D. Figg, Lawrence Yao, Kathleen C. Flanders, Naoko Takebe, Stefanie Sarantopoulos, Susan Booher, Edward W. Cowen Biology of Blood and Marrow Transplantation Volume 21, Issue 6, Pages 1083-1090 (June 2015) DOI: 10.1016/j.bbmt.2015.03.006 Copyright © 2015 Terms and Conditions

Figure 1 Improvement in skin tightness after imatinib therapy. (A) Baseline. (B) After 6 months of treatment, there is increased pigmentation but marked reduction in rippled appearance of the skin (dose, 200 mg daily). (C) End of active treatment (9 months), there is persistent pigmentation but overall marked improvement in ROM. (D) One year after ending active treatment, patient continues to have increased softening of skin fibrosis and reduction in hyperpigmentation (partial response, patient 7). Biology of Blood and Marrow Transplantation 2015 21, 1083-1090DOI: (10.1016/j.bbmt.2015.03.006) Copyright © 2015 Terms and Conditions

Figure 2 Adverse events. Waterfall plot reveals adverse reactions to imatinib in patients with ScGVHD (N = 20). Green bars represent grade 1 adverse events, blue bars represent grade 2 adverse events, and orange bars represent grade 3 adverse events. Biology of Blood and Marrow Transplantation 2015 21, 1083-1090DOI: (10.1016/j.bbmt.2015.03.006) Copyright © 2015 Terms and Conditions

Figure 3 Pharmacokinetics of imatinib treatment in patients with ScGVHD. Data for steady state serum levels in 8 patients receiving imatinib treatment in cohort 2. Levels are superimposed on 100-mg and 200-mg daily dose population controls, shown in black and red, respectively. Patients with ScGVHD show much higher than expected levels at the 200-mg dosing level. One patient had no detectable levels at either time point (not shown). Biology of Blood and Marrow Transplantation 2015 21, 1083-1090DOI: (10.1016/j.bbmt.2015.03.006) Copyright © 2015 Terms and Conditions